The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results.
 
Anthony W. Tolcher
Consulting or Advisory Role - Abbvie
 
Benedito A. Carneiro
Consulting or Advisory Role - EMD Serono; Foundation Medicine; Tempus
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Pfizer (Inst)
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Bayer; Ipsen; Jazz Pharmaceuticals; Millenium Pharamceuticals; Seagen
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Incuron (Inst); Ipsen (Inst); Lilly (Inst); Millenium Pharamceuticals (Inst); Mirati Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst); United Therapeutics (Inst); Vertex (Inst)
 
Albiruni Ryan Abdul Razak
Consulting or Advisory Role - Adaptimmune; Bayer; Merck
Research Funding - Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Bristol-Myers Squibb; Deciphera; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Pfizer; Roche/Genentech
 
Young Kwang Chae
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Counsyl; Foundation Medicine; Guardant Health; Hanmi; Immuneoncia; Lilly; Roche/Genentech; Takeda; Tempus
Speakers' Bureau - AstraZeneca; Genentech/Roche; Lilly; Merck
Research Funding - Abbvie; Biodesix; Bristol-Myers Squibb; Freenome; Lexent Bio
Travel, Accommodations, Expenses - Hanmi
 
Jeannine A. Villella
No Relationships to Disclose
 
Sheryl Coppola
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Stefan Englert
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Andrew C. Phillips
Employment - AbbVie
Stock and Other Ownership Interests - Abbvie
 
Andrew J. Souers
Employment - AbbVie
Stock and Other Ownership Interests - Abbvie
 
Zeena Salman
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie
 
Sudhir Penugonda
Employment - AbbVie
Stock and Other Ownership Interests - Abbvie
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Bluebird Bio; Carolina BioOncology Institute; Juno Therapeutics; Kite, a Gilead company; Lion Biotechnologies; ZIOPHARM Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Curis; Genentech/Roche; TERUMO; TopAlliance BioSciences Inc
Speakers' Bureau - Bristol-Myers Squibb; Dendreon; Genentech/Roche; Merck
Research Funding - Abbvie; Alkermes; Apros Therapeutics; Arcus Biosciences; AstraZeneca/MedImmune; Atreca (Inst); BioBank Online (Inst); Bristol-Myers Squibb; Calico; CEM Corporation (Inst); Corvus Pharmaceuticals; Curis; EMD Serono; Engineered BioPharmaceuticals (Inst); FLX Bio; Genentech/Roche; Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; Merck (Inst); MT Group (Inst); Precision for Medicine (Inst); Replimune (Inst); Seagen; Sequenom (Inst); STEMCELL Technologies (Inst); Tempest Therapeutics; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
Other Relationship - Ongoing discussions with potential future biopharma and biotech for Human Applications Lab sponsored projects
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; Bayer; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Molecular Templates; Molecular Templates; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech